Insights+ Key Biosimilars Events of September 2020

Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potency. Biosimilars are expected to be a cost-effective alternative to the high-priced branded biologics, offering significant and much-needed cost savings to both payers and the patients. Hence, the providers are more likely to adopt biosimilars as a 'reference…

BySenior EditorOctober 1, 2020

INSIGHTS+

Insights+: COVID-19 Healthcare News Monthly Updates – September 2020

Our planet is facing a major pandemic outbreak due to COVID-19 and health agencies are taking every measure to stop itLife sciences companies are putting all of their efforts into finding a treatment or developing a vaccine for this diseasePharmaShots is keeping a track of all of the important updates in the Life-sciences…

BySenior EditorSeptember 30, 2020

THOUGHTSPOT

COVID-19 – Where Does The Pharmaceutical Industry Go From Here?

With the race to develop an effective vaccine becoming intense, how has the coronavirus pandemic changed the pharmaceutical industry, and what can we expect in the long- and short-term? Let's see.The year 2020, and the new decade as a whole, has definitely got off to the worst possible start and we have a pandemic…

BySenior EditorSeptember 28, 2020

VIEWPOINTS

PharmaShots Interview: Genentech’s Dr. Neil Collinson Shares Insights on Xofluza

In a recent interview with PharmaShots, Dr. Neil Collinson, the Senior Principal Clinical Development Scientist at Genentech / Roche shares his insights and highlights on Xofluza.Shots:The P-III BLOCKSTONE study demonstrated that the proportion of household members who became symptomatically ill following infection with influenza was significantly lower in those treated preventively with Xofluza…

BySenior EditorSeptember 22, 2020

INSIGHTS+

Insights+: The US FDA New Drug Approvals in August 2020

The US FDA has approved multiple NDAs and BLAs in Aug 2020, leading to treatments for patients and advances in the health care industry. The Center for Drug Evaluation and Research (CDER) and Center for Biologics Evaluation and Research (CBER) have approved 69 novel products so far in 2020, including 10 in Aug 2020. Additionally,…

BySenior EditorSeptember 17, 2020

VIEWPOINTS

PharmaShots Interview: Genentech’s Ted Omachi Shares Insights on Xolair (omalizumab) PFS

The US FDA has accepted the sBLA for a new self-administration option for Xolair (omalizumab) across all approved US indications.In an interview with PharmaShots, Ted Omachi the Global Development Leader for Xolair and Senior Medical Director of Product Development Immunology shares details and highlights of Xolair (omalizumab) PFS for self-administration.Shots:A decision on…

BySenior EditorSeptember 7, 2020

INSIGHTS+

Insights+ Key Biosimilars Events of August 2020

Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potencyMylan with its partner Lupin and Biocon launched Nepexto (biosimilar, etanercept) and Semglee (insulin glargine injection) in Germany & in the US, respectively. Additionally, Formycon and Bioeq planned to initiate P-III MAGELLAN-AMD Trial for its FYB203 (biosimilar,…

BySenior EditorSeptember 3, 2020

INSIGHTS+

Insights+: The US FDA New Drug Approvals in July 2020

The US FDA has approved multiple NDAs and BLAs in July 2020, leading to treatments for patients and advances in the health care industry. The Center for Drug Evaluation and Research (CDER) and Center for Biologics Evaluation and Research (CBER) have approved 59 novel products so far in 2020, including 8 in July 2020. Additionally,…

BySenior EditorAugust 27, 2020

THOUGHTSPOT

Medical Representatives Opinion Survey for Business Continuity with New Normal

K. K. Consulting Services has conducted this survey by contacting around 2200 medical representatives across the India using google forms.Objective of SurveyThe purpose of this survey is to design a platform for pharmaceutical sales professionals (PSP) to share their opinion about business continuity challenges faced by them due to the present COVID pandemic situation. The nature…

BySenior EditorAugust 24, 2020

THOUGHTSPOT

COVID-19 Vaccine Distribution the Next Supply Chain Frontier

An overview of various aspects of the supply chain that would be crucial in the production and distribution of COVID-19 Vaccine. Write to us at connect@pharmashots.com if you want a PDF copy of this report.Over the past seven months, the global pandemic caused by the spread of SARS-CoV-2, the virus that leads to coronavirus disease (COVID-19),…

BySenior EditorAugust 13, 2020

Senior Editor

Insights+ Key Biosimilars Events of September 2020

Insights+: COVID-19 Healthcare News Monthly Updates – September 2020

COVID-19 – Where Does The Pharmaceutical Industry Go From Here?

PharmaShots Interview: Genentech’s Dr. Neil Collinson Shares Insights on Xofluza

Insights+: The US FDA New Drug Approvals in August 2020

PharmaShots Interview: Genentech’s Ted Omachi Shares Insights on Xolair (omalizumab) PFS

Insights+ Key Biosimilars Events of August 2020

Insights+: The US FDA New Drug Approvals in July 2020

Medical Representatives Opinion Survey for Business Continuity with New Normal

COVID-19 Vaccine Distribution the Next Supply Chain Frontier

Contact US

FOLLOW US